ATHENA Sweeps 8 Criteria in Blind Tests Across 28 Rare Disease Groups
marinkazitnik · x · 2026-07-07
A research team invited domain experts from 28 rare disease organizations within the Biohub Rare As One network to conduct blind evaluations comparing ATHENA against reference models. The assessment covered various therapeutic cases, including neurodevelopmental disorders, epilepsy, metabolic diseases, and rare cancers. ATHENA outperformed baseline models across all 8 evaluation criteria, showing the most significant improvements in cognitive traceability and the helpfulness of its reasoning. Experts particularly praised its ability to provide evidence chain visualizations.
More from Research
- Artificial Analysis breaks down all sub-evaluations in Intelligence Index v4.3.2 — ArtificialAnlys · 2026-10-27
- Infini-AI Lab open-sources Hermit, a framework for agent harness evolution and continual learning — BeidiChen · 2026-10-27
- Meta FAIR's Self-Direction turns agent failures into reusable LoRA skills, +13.8pp on Terminal-Bench — karen_ullrich · 2026-10-27
- DONIC hits 86.79% on bimanual dexterous tracking, crushing prior SOTA's 9.43% — liuziwei7 · 2026-10-27
- Why don't more LLMs ship 10M-token context? A researcher asks about attention tradeoffs — agarwl_ · 2026-10-27
- PSNR below 15 dB in papers likely means the metric was misused, researcher warns — kwangmoo_yi · 2026-10-27